Overview
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
Status:
Completed
Completed
Trial end date:
2016-08-01
2016-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Gabrail Cancer Center ResearchCollaborators:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc
Criteria
Inclusion Criteria:- Written informed consent in accordance with federal, local, and institutional
guidelines
- Age ≥18 years
- Patients must have a tissue diagnosis of any of the following:
- Small cell lung cancer (SCLC) or poorly differentiated gastroenteropancreatic
neuroendocrine tumor (GEP-NET)
- Poorly differentiated metastatic neuroendocrine tumors of unknown primary origin
- Measurable disease: Any primary and/or metastatic mass reproducibly measurable in one
or two diameters by RECIST 1.1 parameters by cat scan (CT) scan.
- Objective evidence of tumor progression within 4 months prior to study entry, as
defined by serial cat scan (CT) per RECIST 1.1 criteria. (At least a 20% increase in
the sum of diameters of target lesions. In addition, the sum must also demonstrate an
absolute increase of at least 5 mm. The appearance of one or more new lesions is also
considered progression).
- Patients must have received at least one prior line of chemotherapy and must have
exhausted any other standard-of-care treatment option.
- Prior radiation and surgery is allowed. At least 3 weeks should have elapsed from
surgery, chemotherapy, hepatic embolization/ chemoembolization or radioactive isotopes
(i.e. Yttrium 90). In any case, disease progression must be documented after
treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Concomitant octreotide treatment for carcinoid syndrome is allowed for patients whose
tumor has progressed while on octreotide. Patients must have been on a stable dose of
octreotide two weeks prior to enrollment and must remain on a stable dose during the
study.
- Hematological function:
- Total white blood cell count (WBC) > 2,000/mm³
- Absolute neutrophil (ANC) > 1,000/mm³
- Platelet >100,000mm³
- Adequate hepatic function within 14 days prior to C1D1: total direct bilirubin <2
times the upper limit of normal (ULN; 1.0 mg/dL) and alanine aminotransferase (ALT)
<2.5 times ULN (30 U/L). In the case of known (radiological and/or biopsy documented)
liver metastasis, ALT <5.0 times ULN is acceptable.
- Adequate renal function within 7 days prior to C1D1: estimated creatinine clearance of
≥ 30 mL/min, calculated using the formula of Cockcroft and Gault: (140-Age) • Mass
(kg)/(72 • creatinine mg/dL); multiply by 0.85 if female.
- Blood electrolytes should be within the following normal limits:
Bicarbonate (total) 18-30 mEq/L Sodium 135-147 mEq/L Potassium 3.5-5.5 mEq/L Phosphorus
1.8-2.3 mEq/L Magnesium 1.5-3.0 mEq/L Chloride 98-106 mEq/L Calcium (total) 4.5-5.5 mEq/L
- Female patients of child-bearing potential must agree to use dual methods of
contraception and have a negative serum pregnancy test at screening, and male patients
must use an effective barrier method of contraception if sexually active with a female
of child-bearing potential. Acceptable methods of contraception are condoms with
contraceptive foam, oral, implantable or injectable contraceptives, contraceptive
patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is
surgically sterilized or post-menopausal. For both male and female patients, effective
methods of contraception must be used throughout the study and for three months
following the last dose.
Exclusion Criteria:
- Patients who are pregnant or lactating
- Patients with the following tumor types: lung carcinoid, pheochromocytomas,
paragangliomas, medullary thyroid carcinomas, any other tumors with neuroendocrine
features not listed in the inclusion criteria
- Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤3 weeks
prior to C1D1
- Major surgery ≤3 weeks prior to C1D1
- Unstable cardiovascular function:
- Congestive heart failure (CHF) of NYHA Class ≥3 OR
- Myocardial infarction (MI) within 3 months
- Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
within one week prior to first dose; patients with controlled infection or on
prophylactic antibiotics are permitted in the study
- Known to be human immunodeficiency virus (HIV) seropositive
- Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
virus (HCV RNA) or HBsAg (HBV surface antigen)
- Any underlying condition that would significantly interfere with the absorption of an
oral medication
- Patients who have active central nervous system (CNS) malignancy. Asymptomatic small
lesions are not considered active. Treated lesions may be considered inactive if they
are stable for at least 3 months. Patient with malignant cells in their cerebrospinal
fluid (CSF) without CNS symptom may be included.
- Serious psychiatric or medical conditions that could interfere with treatment
- Patients with coagulation problems and active bleeding in the last month (peptic
ulcer, epistaxis, spontaneous bleeding)
- Patients with signs of gastrointestinal obstruction or uncontrolled vomiting or
diarrhea (>3 episodes/week) with electrolyte abnormalities
- Concurrent therapy with approved or investigational anticancer therapeutic agents
other than glucocorticoids
- Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1
day 1